Rational development of tumour antigen-specific immunization in melanoma.
Ther Immunol
; 2(4): 211-25, 1995 Aug.
Article
em En
| MEDLINE
| ID: mdl-9358613
ABSTRACT
The identification and molecular characterization of antigens expressed on tumour cells, but not on most normal host tissues, has opened the possibility of specific immunization in the therapy of cancer, particularly of melanoma. Most antigens defined are class I MHC-binding peptides recognized by CD8+ cytolytic T lymphocytes (CTL). Methodologies for active immunization to induce effective anti-tumour CTL are under development in a number of laboratories, and some of these approaches have entered clinical trials. Optimization of the anti-tumour immune response will depend on a thorough knowledge of the signals required for T cell activation, differentiation, and inactivation.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T Citotóxicos
/
Imunoterapia Ativa
/
Vacinas Anticâncer
/
Melanoma
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Ther Immunol
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Estados Unidos